An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Lilly claims the single-dose versions cost at least 50% less than the list price of other incretin ... versions of Novo Nordisk's GLP-1 agonist drug semaglutide, sold as Wegovy for obesity ...

Tirzepatide has been on the shortage list since 2022 ... of legal cases involving compounded weight-loss drugs, with Novo Nordisk and Lilly both filing lawsuits seeking to block the activity ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...